STOCK TITAN

Treatment.com AI - TREIF STOCK NEWS

Welcome to our dedicated page for Treatment.com AI news (Ticker: TREIF), a resource for investors and traders seeking the latest updates and insights on Treatment.com AI stock.

Company Overview

Treatment.com AI Inc. (TREIF) is an innovative healthcare technology company dedicated to disrupting the conventional approaches within the medical and educational sectors by harnessing advanced AI healthcare and AI-driven clinical insights. With over seven years of evolution and collaboration with hundreds of global healthcare professionals, the company has built a comprehensive, personalized AI engine known as the Global Library of Medicine (GLM). This platform not only delivers highly accurate clinical information but also significantly reduces diagnostic uncertainties and administrative inefficiencies across medical institutions.

Core Business Areas and Technology

Treatment.com AI specializes in a dual-focused approach: enhancing medical education and reinforcing clinical decision support. The company's flagship product, the Medical Education Suite (MES), is designed specifically for medical and nursing schools to automate and streamline the creation, grading, and administration of national exams such as Objective Structured Clinical Examinations (OSCEs). By integrating the MES with its robust GLM—a repository built with inputs from credentialed clinicians—the company ensures that case testing, scoring, and clinical reasoning training are accomplished with unparalleled consistency and efficiency.

The Global Library of Medicine (GLM) itself is the cornerstone of Treatment.com AI’s offerings. Leveraging sophisticated AI algorithms, the GLM provides clinicians with real-time diagnostics support, including first diagnosis accuracy, recommended tests (physical and lab), and imaging protocols, while also suggesting appropriate billing codes. This meticulous integration of clinical expertise and deep learning algorithms positions the GLM as a key asset in reducing operational burdens and improving patient care quality.

Operational Model and Market Position

The company generates revenue primarily through subscription-based SaaS solutions, licensing its technologically advanced platforms to educational institutions and health service providers. By focusing on reducing the time, resources, and costs associated with medical examinations and administrative processes, Treatment.com AI positions itself as a vital partner in both the academic and clinical healthcare landscapes. Its products are used globally in environments that demand high consistency in assessment and diagnostic accuracy, making them essential tools for large-scale healthcare education and patient management.

Treatment.com AI’s market presence is further solidified through strategic collaborations and partnerships with key industry players. These partnerships enable the company to explore new applications in health risk assessments, virtual care interfaces, and innovative solutions for digital health, thereby expanding its influence across the healthcare continuum. In an industry where digital transformation is increasingly important, Treatment.com AI stands out by integrating best clinical practices with evidence-based AI innovations.

Key Product Features

  • Medical Education Suite (MES): Designed to automate the processes involved in creating exam cases, grading, and delivering instant feedback to both educators and students. This solution reduces administrative overhead and optimizes resource allocation in medical institutions.
  • Global Library of Medicine (GLM): Provides comprehensive and real-time clinical support that aids healthcare professionals in decision-making. It features extensive data reviews, symptom probability explanations, and personalized recommendations backed by a global network of experts.
  • AI Diagnostics and Decision Support Tools: These include solutions like AI Patient and AI Doctor in a Pocket. They offer mobile-friendly, on-the-go support that enhances physician diagnostic capabilities and provides educational enrichment for medical students.

Industry Relevance and Technological Advantages

In an era where digital health and AI applications are becoming central to healthcare reforms, Treatment.com AI has positioned itself at the nexus of innovation and everyday clinical practice. Its AI engine harnesses the power of machine learning and large language models to offer a nuanced diagnostic support system that is both efficient and reliable. The GLM’s high diagnostic accuracy, achieved through rigorous clinical validation, underscores the company's commitment to using AI for augmenting human expertise in a balanced and responsible manner.

The company’s focus on reducing administrative burdens and streamlining exam processes places it in a unique competitive category. Unlike other health tech firms that may offer piecemeal solutions, Treatment.com AI provides an integrated platform that spans from education to clinical decision support, thereby bridging critical gaps within the healthcare workflow.

Strategic Partnerships and Collaborative Efforts

Treatment.com AI has established meaningful collaborations with academic institutions, healthcare navigation platforms, and medical technology firms. These include engagements with renowned medical schools and internationally recognized universities, ensuring that the company’s solutions are consistently tested against the highest educational and clinical standards. Additionally, partnerships with healthcare navigation services enrich the company’s ecosystem by bridging clinical AI support with broader patient management initiatives.

These alliances enhance the credibility of Treatment.com AI’s offerings, as the company not only provides standalone AI tools but also integrates them within larger, real-world applications that address both educational needs and operational challenges in healthcare settings. This collaboration with multiple stakeholders reinforces the value proposition through shared expertise and collective advancement in the field.

Client and End-User Benefits

The benefits of Treatment.com AI’s solutions are multifaceted. For medical educators, the MES simplifies the exam creation and grading process, significantly cutting down the time and cost involved in traditional assessment methods. For healthcare professionals and students, the GLM provides immediate, contextually relevant clinical insights that enhance decision-making and learning outcomes, even under high-pressure conditions such as clinical examinations and emergency care scenarios.

Across the board, Treatment.com AI aids in reducing administrative overload, allowing clinicians more time for patient care while providing structured, data-driven support that improves both diagnostic and educational standards. These benefits extend to healthcare institutions as a whole, where the standardization and automation of clinical processes lead to higher operational efficiencies and more consistent quality in patient outcomes.

Conclusion

Treatment.com AI Inc. exemplifies the integration of artificial intelligence within healthcare, offering a robust platform that combines the depth of clinical knowledge with cutting-edge AI technology. Its commitment to accuracy, efficiency, and comprehensive support in both medical education and clinical practice makes it a noteworthy entity in the evolving digital health landscape. With its dual focus on streamlining clinical assessments and empowering healthcare professionals with reliable decision support tools, Treatment.com AI continues to influence how healthcare systems approach education, diagnostics, and ultimately patient care.

The thoroughness in design, collaborative industry partnerships, and an enduring commitment to clinical excellence ensure that Treatment.com AI remains an informative and essential resource for institutions seeking to leverage AI in addressing long-standing challenges in the healthcare sector.

Rhea-AI Summary

Treatment.com AI (TREIF) has signed a Collaborative Agreement with Beijing Aiyi Botong Information Technology (Aiyibotong) to explore commercial opportunities for Clinical Decision Support Systems (CDSS) in China and Far East markets. The partnership aims to combine Treatment's Global Library of Medicine (GLM) with Aiyibotong's CDSS technology.

Key highlights:

  • China's CDSS market expected to reach ~US$600 million by 2030
  • Aiyibotong has installations in over 200 healthcare institutions in China
  • Digital Health investment in China projected to hit US$45 billion in 2025

The collaboration focuses on:

  • GLM content localization and alignment with Chinese medical consensus
  • Technology licensing and CDSS platform integration
  • Co-marketing initiatives in China
  • Development of AI-based CDSS for the global market

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.55%
Tags
AI
-
Rhea-AI Summary

Treatment.com AI (TREIF) has signed a Collaborative Agreement with Beijing Aiyi Botong Information Technology (Aiyibotong) to explore commercial opportunities for Clinical Decision Support Systems (CDSS) in China and Far East markets. The partnership aims to combine Treatment's Global Library of Medicine (GLM) with Aiyibotong's CDSS technology.

Key highlights:

  • China's CDSS market expected to reach ~US$600 million by 2030
  • Aiyibotong has installations in over 200 healthcare institutions in China
  • Digital Health investment in China projected to hit US$45 billion in 2025

The collaboration includes GLM content localization, technology licensing, co-marketing initiatives, and joint development of AI-based CDSS for the global market. The agreement was signed on February 19, 2025, with no associated costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.55%
Tags
AI
-
Rhea-AI Summary

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) announces significant growth of Rocket Doctor's virtual healthcare platform in Alberta. The platform has served over 71,000 Albertans, with 35% from communities under 25,000 population.

Key achievements include:

  • 112% increase in patient visits year-over-year, serving 36,779 patients
  • 218% growth in new physicians joining the platform, with 48 new doctors onboard
  • 4.4-star Google rating from over 2,400 reviews

Rocket Doctor's model enables independent physicians to operate efficiently while covered under Alberta's provincial health insurance. The company plans to integrate AI-driven tools and expand its services across Canada. Treatment.com AI Inc. has a definitive share purchase agreement dated February 11, 2025, to acquire Rocket Doctor Inc.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) announces significant growth of Rocket Doctor in Alberta, showcasing impressive metrics in healthcare accessibility. The virtual healthcare marketplace has served over 71,000 Albertans, with 35% from communities under 25,000 population.

Key achievements include a 112% year-over-year increase in patient visits, totaling 36,779 patients, and a remarkable 218% growth in new physicians joining the platform. The platform maintains a strong 4.4-star rating on Google with over 2,400 reviews.

Rocket Doctor's unique model supports independent doctors with technology and administrative support, covered under Alberta's provincial health insurance. The company is focused on expanding its physician network and integrating AI-driven tools to improve healthcare accessibility across the province.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Treatment.com AI Inc. (OTC: TREIF) has successfully closed its upsized brokered private placement, raising $3.3 million through the issuance of 6,600,000 units at $0.50 per unit. Each unit includes one common share and half a share purchase warrant, with warrants exercisable at $0.75 until March 13, 2027.

The company paid the underwriter, Ventum Capital Corp., a cash commission of $264,000 and issued 528,000 non-transferable broker warrants. The proceeds will be allocated to sales and administrative expenses, software research and development, and working capital purposes.

Treatment.com AI specializes in healthcare AI technology, having developed the Global Library of Medicine (GLM), an AI engine built with input from hundreds of healthcare professionals. The GLM platform provides clinical information, recommended tests, and billing codes to healthcare professionals, aiming to reduce administrative burden and improve patient care quality.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
Rhea-AI Summary

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) has announced that Rocket Doctor has been approved as an in-network provider for New York Medicaid, giving 6.9 million beneficiaries (35% of the state's population) access to virtual healthcare services.

Starting January 22, 2025, Rocket Doctor's board-certified physicians will offer primary, urgent, and specialty care to Medicaid recipients through its telehealth platform, with accreditation valid until 2030. This initiative aims to reduce ER visits, decrease wait times, and improve access to timely specialist referrals.

Additionally, Rocket Doctor is collaborating with EngageWell, a network of health and human service organizations serving low-income populations in New York City. This partnership, supported by a US$1 million grant, will enhance virtual care for aging New Yorkers through telehealth, remote patient monitoring, and addressing social determinants of health.

Clients served by any EngageWell provider can now book virtual consultations with Rocket Doctor's network of physicians across more than 20 specialties, aiming to streamline access to outpatient care and improve healthcare outcomes while reducing costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.17%
Tags
partnership
Rhea-AI Summary

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) announced that Rocket Doctor has been approved as an in-network provider for New York Medicaid, giving 6.9 million beneficiaries (35% of the state's population) access to virtual healthcare services. Starting January 22, 2025, Rocket Doctor's board-certified physicians will offer primary, urgent, and specialty care through their telehealth platform, with accreditation valid until 2030.

Additionally, Rocket Doctor is collaborating with EngageWell, a network of health and human service organizations serving low-income populations in New York City. This partnership, supported by a US$1 million grant, aims to enhance virtual care for aging New Yorkers through telehealth, remote patient monitoring, and addressing social determinants of health.

The initiative is designed to reduce ER visits, decrease wait times, and improve access to timely specialist referrals, particularly for underserved communities who can now receive care from home.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.17%
Tags
partnership
-
Rhea-AI Summary

Treatment.com AI has announced the release of its updated Medical Education Suite (MES), coinciding with their participation in the AI Assessment Symposium at the University of Minnesota Medical School. The enhanced MES platform aims to support OSCE exams, taken by 200,000-300,000 medical students globally each year. New features include AI Patient for exam preparation, expanded OSCE Case Packages, and an AI Prep Tool with guided and non-guided learning options. The company plans further developments including AI Doctor in a Pocket and Audio/Video Analysis capabilities through 2024 and early 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
AI
-
Rhea-AI Summary

Treatment.com AI has launched an updated Medical Education Suite (MES) coinciding with their participation in the AI Assessment Symposium at the University of Minnesota Medical School. The enhanced platform aims to support OSCE exams, taken by 200,000-300,000 medical students globally annually. New features include AI Patient for exam preparation, expanded OSCE Case Packages planned for up to 100 cases through Q4 2024, and an AI Prep Tool with guided and non-guided learning support. Future developments include AI Doctor in a Pocket and Audio/Video Analysis capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
AI
Rhea-AI Summary

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) announces its participation in the 2024 Cantech Letter Investment Conference on October 9, 2024 in Toronto, Ontario. CEO Dr. Essam Hamza will deliver an investor presentation at 11:00 AM ET and participate in 1-on-1 meetings with investors. The event will take place at the Arcadian Loft, 8th floor, 401 Bay Street.

Dr. Hamza emphasized the conference's importance, stating, "The healthcare system is at the precipice of substantial modernization and we believe that our proprietary platform can help with reducing its inefficiencies, reducing administration headaches, and ultimately improving patient access and care." Interested parties can contact tara@cantechletter.com to register or schedule 1-on-1 meetings with Treatment.com AI.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
conferences AI

FAQ

What is the current stock price of Treatment.com AI (TREIF)?

The current stock price of Treatment.com AI (TREIF) is $0.3158 as of April 21, 2025.

What is the market cap of Treatment.com AI (TREIF)?

The market cap of Treatment.com AI (TREIF) is approximately 16.7M.

What is the core business of Treatment.com AI?

Treatment.com AI focuses on using advanced artificial intelligence to enhance medical education and provide clinical decision support. Its platforms streamline exam processes and offer real-time diagnostic insights for healthcare professionals.

How does the Medical Education Suite (MES) improve medical training?

The MES automates the creation, grading, and feedback processes for medical exams, such as OSCEs, reducing administrative burdens and enabling more efficient and standardized clinical skills assessments for students.

What role does the Global Library of Medicine (GLM) play?

The GLM is a comprehensive, AI-powered repository of clinical information that aids in diagnostic decision-making by providing evidence-based recommendations, test protocols, and detailed clinical insights supported by global expert reviews.

How does Treatment.com AI generate revenue?

The company derives revenue through subscription-based SaaS models, licensing of its AI technology to educational institutions and healthcare providers, and strategic partnerships that integrate its solutions into broader clinical and operational frameworks.

What differentiates Treatment.com AI from its competitors?

Its unique integration of an extensively vetted Global Library of Medicine with automated educational tools in the MES, combined with real-time clinical decision support, sets it apart by addressing both educational and diagnostic needs in a unified platform.

Who are the primary users of Treatment.com AI's solutions?

Primary users include medical and nursing schools, individual healthcare professionals, and institutions seeking to reduce administrative overhead while improving diagnostic accuracy through AI-driven insights.

How does the company ensure the clinical accuracy of its AI tools?

Clinical accuracy is maintained through collaboration with hundreds of credentialed clinicians and continuous validation of the AI algorithms, ensuring that recommendations and diagnostic insights are both reliable and evidence-based.

What markets does Treatment.com AI serve?

The company serves global markets, with significant adoption in North American and international medical and nursing schools, as well as a growing presence in clinical decision support for healthcare providers worldwide.

Can Treatment.com AI's solutions assist in reducing healthcare operational costs?

Yes, by automating exam assessments and providing real-time diagnostic recommendations, the company’s solutions help reduce administrative tasks and optimize resource allocation, thereby lowering operational costs.

What strategic partnerships has Treatment.com AI formed?

Treatment.com AI has formed partnerships with academic institutions, healthcare navigation platforms, and digital health firms, enabling the integration of its AI tools into broader clinical and educational ecosystems.
Treatment.com AI

OTC:TREIF

TREIF Rankings

TREIF Stock Data

16.69M
71.65M
7.52%
0.59%
Health Information Services
Healthcare
Link
Canada
Vancouver